Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

o, statements about the Company's product development and commercialization schedule, including, particularly, future plans with respect to its Amoxicillin PULSYS products; any statements regarding Dr. Rudnic's comments and expectations concerning the Company; the Company's initiatives to develop improved antibiotics; the Company's existing and anticipated collaborative agreements; and any financial forecasts and projections for 2008 and thereafter included under the Financial Guidance section of this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) maintain its Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and pr
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... have shelled out for crude 3-D glasses, polarized ... experience. These basic devices, used to trick the ... soon be rendered obsolete with the introduction of ... researchers. , TAU doctoral students Yuval Yifat, Michal ... holography based on nanoantennas that could be used ...
(Date:1/15/2014)... an approach akin to assembling a club sandwich ... Technology (NIST) researchers have succeeded in crafting a ... flammability of foam commonly used in upholstered furniture ... the nanotube-coated polyurethane foam was reduced 35 percent ...
Breaking Biology Technology:Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... 28 Cylene Pharmaceuticals has appointed,Dr. Kenna Anderes ... 17 years,of life sciences research experience with a ... President of Cancer Biology. With Cylene,s,most advanced compound, ... will be leading Cylene,s biology and pre-clinical research,teams ...
... - Oncothyreon Inc. (the,"Company") (Nasdaq: ONTY ) ... innovative therapeutic products for the treatment of,cancer, today ... plans,and corporate objectives for 2008. Oncothyreon is developing ... the potential to,improve the lives and outcomes of ...
... MNKD ), focused on discovering, developing and,commercializing treatments ... at the Wachovia Healthcare Conference on January 30, 2008 ... MA., Interested parties can access a link to ... Relations section of the Company,s website at, http://www.mannkindcorp.com . ...
Cached Biology Technology:Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology 2Oncothyreon highlights corporate and clinical objectives for 2008 2Oncothyreon highlights corporate and clinical objectives for 2008 3Oncothyreon highlights corporate and clinical objectives for 2008 4Oncothyreon highlights corporate and clinical objectives for 2008 5
(Date:7/10/2014)... 2014 Amyloid diseases, such as Alzheimer,s disease, ... all share the common trait that proteins aggregate ... in vitro studies have found that neither the ... very toxic. New evidence using two-dimensional infrared (2D ... the amylin aggregation pathway that may explain toxicity, ...
(Date:7/10/2014)... (July 10, 2014) New research from The University ... that It,s Your GameKeep it Real (IYG), a health ... healthy dating relationships, can significantly reduce dating violence behaviors ... Disease Control and Prevention, 10 percent of high school ... studies suggest that more than 20 percent are victims ...
(Date:7/10/2014)... NOAA and its research partners predict that western Lake ... toxic blue-green algae, during the 2014 bloom season in ... be smaller than last year,s intense bloom, and considerably ... will vary across the lake,s western basin and are ... how far it spreads. , Harmful algal blooms ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 2NOAA, partners predict significant harmful algal bloom in western Lake Erie this summer 3
... MABrown seems to be the color of choice when it comes to ... while its counterpart, white fat stores it. The danger in white fat ... poses, seems especially linked to visceral fat. Visceral fat is the build-up ... in the battle against obesity, brown fat appears to be our friend ...
... This release is available in German . ... plant species develop special strategies. These differ in part considerably ... Ingolf Khn and Dr. Sonja Knapp of the Helmholtz Centre ... published in the current issue of the scientific journal ...
... NOAA scientists and their colleagues have discovered a biological ... mammals that shows when they have been repeatedly exposed ... toxic at high levels. While little is ... marine animals or humans, high-level exposure through eating contaminated ...
Cached Biology News:A new candidate pathway for treating visceral obesity 2Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3NOAA discovers way to detect low-level exposure to seafood toxin in marine animals 2
Monoclonal antibodies conjugated with rhodamine...
... p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl White ... Protein synthesis inhibitor. Inhibits translation by ... chains. Induces DNA fragmentation in thymocytes ... Purity: ≥98% by TLC. ...
Mouse monoclonal antibody to PPP2R2C - protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform...
...
Biology Products: